Can-Fite BioPharma completes RA Stage III study of lead drug applicant CF101 Can-Fite BioPharma Ltd.

Can-Fite CEO Pnina Fishman stated, ‘We are very pleased that the Stage III style is completed and based on the positive data of the last Phase II study we think that increasing the drug dosage will yield positive data and those patients with RA can reap the benefits of our oral drug.’ According to independent business details company visiongain, the global RA medication market is likely to generate revenues of $38.5bn in 2017. Can-Fite's Stage II/III psoriasis trial is ongoing with data likely to be released in the initial quarter of 2015.. Can-Fite BioPharma completes RA Stage III study of lead drug applicant CF101 Can-Fite BioPharma Ltd.Between nine and 10 million people world-wide die of cancer each year, says Kalluri. While a lot has been learned of how genetic defects convert regular cells into cancerous cells, much less is known about how exactly the physical body defends itself against the growth of cancer. Our study helps give a glimpse into what could be happening. The wish is that new understanding of cancer development can eventually lead to the use of these natural proteins as therapies to treat tumor at an early on stage, before it turns into a devastating disease.